Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Absence of herb-drug interactions of mistletoe with the tamoxifen metabolite (E/Z)-endoxifen and cytochrome P450 3A4/5 and 2D6 in vitro
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 4500786
Author(s) Weissenstein, Ulrike; Kunz, Matthias; Oufir, Mouhssin; Wang, Jue Theresa; Hamburger, Matthias; Urech, Konrad; Regueiro, Ursula; Baumgartner, S.
Author(s) at UniBasel Hamburger, Matthias
Oufir, Mouhssin
Wang, Jue Theresa
Year 2019
Title Absence of herb-drug interactions of mistletoe with the tamoxifen metabolite (E/Z)-endoxifen and cytochrome P450 3A4/5 and 2D6 in vitro
Journal BMC complementary and alternative medicine
Volume 19
Number 1
Pages / Article-Number 23
Mesh terms Apoptosis, drug effects; Cell Cycle, drug effects; Cell Proliferation, drug effects; Cytochrome P-450 CYP2D6, metabolism; Cytochrome P-450 CYP3A, metabolism; Herb-Drug Interactions; Humans; MCF-7 Cells; Plant Extracts, pharmacology; Tamoxifen, pharmacology; Viscum album, chemistry
Abstract Background Women diagnosed with breast cancer frequently seek complementary and alternative (CAM) treatment options that can help to cope with their disease and the side effects of conventional cancer therapy. Especially in Europe, breast cancer patients use herbal products containing mistletoe (Viscum album L.). The oldest and one of the most prescribed conventional drugs for the treatment of estrogen receptor positive breast cancer is tamoxifen. Aside from positive clinical experience with the combination of tamoxifen and mistletoe, little is known about possible herb-drug interactions (HDIs) between the two products. In the present in vitro study, we investigated the effect of standardized commercial mistletoe preparations on the activity of endoxifen, the major active metabolite of tamoxifen. Methods The estrogen receptor positive human breast carcinoma cell line MCF-7 was treated with (E/Z)-endoxifen hydrochloride in the presence and absence of a defined estradiol concentration. Each concentration of the drug was combined with fermented Viscum album L. extracts (VAE) at clinically relevant doses, and proliferation, apoptosis and cell cycle were analyzed. In parallel, possible inhibition of CYP3A4/5 and CYP2D6 was investigated using 50-donor mixed gender pooled human liver microsomes (HLMs). Results VAE did not inhibit endoxifen induced cytostasis and cytotoxicity. At higher concentrations, VAE showed an additive inhibitory effect. VAE preparations did not cause inhibition of CYP3A4/5 and CYP2D6 catalyzed tamoxifen metabolism. Conclusions The in vitro results suggest that mistletoe preparations can be used in combination with tamoxifen without the risk of HDIs. Electronic supplementary material The online version of this article (10.1186/s12906-019-2439-2) contains supplementary material, which is available to authorized users.
Publisher BioMed Central
ISSN/ISBN 1472-6882
URL https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339413/
edoc-URL https://edoc.unibas.ch/70144/
Full Text on edoc No
Digital Object Identifier DOI 10.1186/s12906-019-2439-2
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/30658716
Document type (ISI) Journal Article
 
   

MCSS v5.8 PRO. 0.330 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
19/04/2024